Trial: BMD5
Aspirin Events/Patients (%): 13/3,429
(0.38)
Control Events/Patients (%): 6/1,710
(0.35)
Odds Ratio (95% CI): 1.08 (0.41 to 2.85)
Duration of Therapy: 5.8 years
Annual Approximate Control Group Risk: 0.06%
Approximate Excess Bleeding Events per 1,000 Patients Treated per Year: 0.05
Trial: PHS4
Aspirin Events/Patients (%): 23/11,037
(0.21)
Control Events/Patients (%):12/11,034
(0.11)
Odds Ratio (95% CI): 1.92 (0.95 to 3.86)
Duration of Therapy: 5 years
Annual Approximate Control Group Risk: 0.02%
Approximate Excess Bleeding Events per 1,000 Patients Treated per Year: 0.2
Trial: TPT7
Aspirin Events/Patients (%): 3/1,268
(0.24)
Control Events/Patients (%): 2/1,272
(0.16)
Odds Ratio (95% CI): 1.51 (0.25 to 9.03)
Duration of Therapy: 6.8 years
Annual Approximate Control Group Risk: 0.02%
Approximate Excess Bleeding Events per 1,000 Patients Treated per Year: 0.12
Trial: HOT8
Aspirin Events/Patients (%): 14/9,399
(0.15)
Control Events/Patients (%): 15/9,391
(0.16)
Odds Ratio (95% CI): 0.93 (0.45 to 1.93)
Duration of Therapy: 3.8 years
Annual Approximate Control Group Risk: 0.04%
Approximate Excess Bleeding Events per 1,000 Patients Treated per Year: 0.03 fewer events
Trial: PPP9
Aspirin Events/Patients (%): 2/2,226
(0.08)
Control Events/Patients (%): 3/2,269
(0.13)
Odds Ratio (95% CI): 0.67 (NR)
Duration of Therapy: 3.6 years
Annual Approximate Control Group Risk: 0.04%
Approximate Excess Bleeding Events per 1,000 Patients Treated per Year: 0.12 fewer events
*BMD indicates British Male Doctors' Trial; HOT, Hypertension Optimal Treatment Trial; NR, not reported; PHS, Physicians' Health Study; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial.